Ethyl Acetate

Ethyl Acetate

SCHEMBL4731093

CC(C)CCCC(Cl)Cl.CCOC(C)=O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
LMNA P02545 2/20 0.52
HSD17B10 Q99714 1/20 0.52
PTPN1 P18031 1/20 0.44
BLM P54132 1/20 0.36
TSHR P16473 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
ALOX15 P16050 5/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
SOAT1 P35610 1/20 0.31
MMP8 P22894 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL28478460 0.83 ALDH1A1 (0.54) ALDH1A1LMNAHSD17B10TSHRCNR1
Ethyl Acetate SCHEMBL10854118 0.83 ALDH1A1 (0.54) ALDH1A1LMNAHSD17B10TSHRCNR1
Ethyl Acetate SCHEMBL1268307 0.81 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10CNR1CNR2
Ethyl Acetate SCHEMBL148560 0.81 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10CNR1CNR2
Ethyl Acetate SCHEMBL29038293 0.81 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10CNR1CNR2
Ethyl Acetate SCHEMBL278533 0.81 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10CNR1CNR2
Ethyl Acetate SCHEMBL2534820 0.81 ALDH1A1 (0.56) ALDH1A1LMNAHSD17B10PTPN1TP53
Ethyl Acetate SCHEMBL8532167 0.80 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10CNR1CNR2
Ethyl Acetate SCHEMBL9486136 0.80 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL58459 0.80 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008032060-A1 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032077-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
US-7101895-B2 Cyclohexyl sulphone derivatives as gamma-secretase inhibitors MERCK SHARP & DOHME LIMITED (GB) 2006-09-05 US disclosed
US-20040122050-A1 Cyclohexyl sulphone derivatives as gamma-secretase inhibitors MERCK SHARP & DOHME LTD. (GB) 2004-06-24 US disclosed
EP-0915879-A1 NOVEL COMPOUNDS Astra Pharmaceuticals Limited (GB) 1999-05-19 EP disclosed
WO-1998001449-A1 NOVEL COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1998-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122050-A1 Cyclohexyl sulphone derivatives as gamma-secretase inhibitors BACE1, BACE2, APP ALDH1A1 1283/4885LMNA 1703/4885HSD17B10 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.